Bradley Cocks

BDAC | Control Your Narrative. Digital Marketing for Investor Relations

[Arovella Therapeutics ASX: ALA @WeAreArovella]

Welcome to Arovella Therapeutics, at the time of making his video, we are the only Australian biotech company developing an iNKT cell therapy platform.

Watch the full video on our YouTube channel:
https://t.co/VcVikO4qFp

[Bradley Cocks @Bradley_Cocks]

@Chimeric $CHM now has 4 clinical trials being conducted under 5 Investigational New Drug allowances from the FDA - very, very, few ASX biotechs have a pipeline as rich as this.

[Arovella Therapeutics ASX: ALA @WeAreArovella]

INVESTOR WEBINAR
11:00 AM (AEST)
Thursday, June 22nd

To discuss the next steps for Arovella and the opportunities with developing our iNKT cell platform.

Presented by Dr Michael Baker, MD & CEO.

Register now:
https://t.co/oHhkxy9s3b

$ALA $ALA.ax #celltherapy #iNKT #medtech

[Arovella Therapeutics ASX: ALA @WeAreArovella]

Arovella releases cancer treatment data $ALA https://t.co/dXYfPUCIS9

[Bradley Cocks @Bradley_Cocks]

Just Listed | 49 Eridge Park Road, Burradoo

A secluded, grand family estate on 20 sweeping acres with extraordinary potential.

⤵
https://t.co/FZ5NQr26pl

#southernhighlandsnsw #burradoo #bowral #nsw
#mossvale #thehighlands #southernhighlands

[Arovella Therapeutics ASX: ALA @WeAreArovella]

Video Replay | Explanatory Webinar $ALA

Presented by Dr Mini Bharathan & Dr Michael Baker. Learn about the impressive preclinical data from our iNKT cell therapy platform and how our manufacturing process is truly differentiated.

https://t.co/De4XEwbYBG

#iNKT #CellTherapy #ASX

[Radiopharm Theranostics @TeamRadiopharm]

Click to visit our YouTube channel https://t.co/CQVCWkHMJm and watch Riccardo Canevari's latest video on Wholesale Investor's 'Executive Interviews.' $RAD $RAD.ax

[Radiopharm Theranostics @TeamRadiopharm]

"We are confident obtaining a listing on Nasdaq will complement our loyal existing Australian shareholder base by expanding our access to investors globally, & thereby driving increased shareholder value with enhanced liquidity." - CEO, Riccardo Canevari

https://t.co/qamuwhMC71

[We Are Tennis @WeAreTennis]

The one and only Roger Federer.

(via @Olly_Tennis_)

[Radiopharm Theranostics @TeamRadiopharm]

We are pleased to share our mention in the Small Caps interview below:

"All these companies regardless of their share performances this year have potentially “transformational” events in 2023 with clinical trials and high risk/high reward drilling." $RAD

https://t.co/sBLMQyJian

[Arovella Therapeutics ASX: ALA @WeAreArovella]

“This is another important step forward for Arovella. From a business perspective, we intend to create a larger technology gap between ourselves and competitors in the #oncology drug development market ..." - Michael Baker CEO $ALA #CellTherapy

Learn more https://t.co/WuNaLMJ0zR

[Arovella Therapeutics ASX: ALA @WeAreArovella]

We are pleased to share our December 2022 Newsletter - read and subscribe below:

https://t.co/wjZCAMPSDg

$ALA.ax $ALA #CellTherapy #iNKT #CancerResearch

[Radiopharm Theranostics @TeamRadiopharm]

New Analyst Coverage:
Brookline Capital Markets

Download the PDF: https://t.co/gpH6K26SsJ

$RAD $RAD.ax #radiopharmaceutical #biotech #asx

[Arovella Therapeutics ASX: ALA @WeAreArovella]

We are pleased to be mentioned in Merchant #Biotech Fund's November 2022 Newsletter:

"... highlights the huge potential we see in #CellTherapy, and why we have taken a position in early-stage Cell Therapy investments such as Arovella Therapeutics."

$ALA: https://t.co/LVAfP5qiIw

[Radiopharm Theranostics @TeamRadiopharm]

"This is an outstanding endorsement of our RAD201 technology that gives us added confidence to develop this asset even further. HER2 positive breast cancer is around 15-20% of all #breastcancer cases ..."

- Riccardo Canevari, CEO $RAD $RAD.ax

Read more: https://t.co/3JSeckXMaH

[Imugene | Cancer Immunotherapies @TeamImugene]

Watch Leslie Chong's interview following our #ASX news of our positive new HER-Vaxx HERIZON data presented at ESMO Asia 2022. $IMU $IMU.ax

Full interview via our YouTube channel:
https://t.co/ndGeTgj1vh

[Radiopharm Theranostics @TeamRadiopharm]

“We are delighted to be extending & strengthening our partnership with GenesisCare, a world-leader in cancer care, to advance the future of radiopharmaceuticals and improve access to innovative therapies for patients all over the world.” - Mr Canevari $RAD
https://t.co/inOsNlr4SB

[Proactive Australia @proactive_au]

$RAD Radiopharm Theranostics welcomes additional data from Phase 2a brain metastases trial https://t.co/ASLxtqAXcU @TeamRadioPharm #RAD #ASX #ASXNews

[Radiopharm Theranostics @TeamRadiopharm]

“ANSTO is one of Australia’s largest public research organisations and is widely recognised as an international leader in the field of nuclear science and technology ..." - CEO Mr. Riccardo Canevari $RAD

Full video: https://t.co/rJYSAUAaJp

@ANSTO @GenesisCare @radiopharm4cure

[Radiopharm Theranostics @TeamRadiopharm]

We are pleased to announce an agreement with Australia's Nuclear Science and Technology Organisation (@ANSTO) to supply us with an isotope non-carrier-added lutetium-177 (Lu-177) for trials in Australia.

Learn more: https://t.co/5pDIc2DtLm
$RAD $RAD.ax